



Diagnósticos da América S.A.

Investor Relations
Av. Juruá, 434 – Alphaville, Barueri – SP
55 11 4197-5410
55 11 4197-5509
ir@danet.com.br
www.diagnosticosdaamerica.com.br



MATERIAL FACT

DIAGNÓSTICOS DA AMÉRICA S.A. CNPJ: 61.486.650/0001-83

Pursuant to CVM Instruction no. 358/2002 and the laws in effect, Diagnósticos da América S.A. (Bovespa: DASA3) hereby announces the following to its stockholders and to the market:

1. Diagnósticos da América S.A. ("DASA") has acquired 21,371,573 common nominative shares or 92.92% of the 23,000,000 shares that constitute the capital stock of Laboratório Frischmann Aisengart S.A.. The transaction value, totaling R\$ 30,000,000.00, was paid with DASA's own resources, R\$ 27,000,000.00 of which came from its clinical analysis operations and R\$ 3,000,000.00 from imaging diagnosis, environmental analyses, genetically modified organisms analyses and toxicological analyses, which represent DASA's entry into new market segments.

2. Mr. James Frischmann Aisengart remains as a minority stockholder, holding 7.08% of the laboratory's capital stock or 1,628,427 of its common shares. Mr. Aisengart does not participate in company management and faces litigation against Laboratório Frischmann Aisengart S.A. and its former stockholders.

3. The operation was approved by the DASA's Board of Directors in a meeting held on July 5, 2005 and, as per Article no. 256 of Act no. 6.404/76, it will be submitted to the stockholders for ratification in a Shareholders' General Meeting to be summoned within a maximum period of 15 days as of this date, but it is still subject to subsequent approval by the Brazilian Antitrust Commission (CADE).

São Paulo, July 06, 2005

Marcelo Marques Moreira Filho
CFO and Investor Relations Director

